Similarly, p53 promoter methylation results in deactivation and causes an increased risk of cancers such as breast carcinomas, gliomas, acute lymphoblastic leukemia, hepatocellular carcinomas, and ovarian cancer [40–44], as well as ESCC in the study area specifically. Here, TP53 is linked to hepatocellular carcinoma.